A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas

Lynn G. Feun, David J. Stewart, Moshe Maor, Milam Leavens, Niramol Savaraj, M. Andrew Burgess, Wai Kwan A. Yung, Robert S. Benjamin

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

A pilot study was performed combining cis-diamminedichloroplatinum (CDDP) and radiation therapy to treat patients with high-grade astrocytomas. CDDP at a dose of 40 mg/ m2/ week intravenously was given during the course of cranial irradiation. Following irradiation, CDDP was given every three weeks on a schedule of 35-40 mg/ m2/ day for three days until toxicity became unacceptable or until tumor progression occurred. Radiation therapy consisted of 6 000 rads over a seven week period or 5 000 rads followed by an additional 1500 rads to the tumor site. Patients were followed by computerized axial tomography (CT) scan and neurologic examination. Thirty patients were entered onto the study; 22 were considered evaluable. The median survival was 53 weeks and the median time to progression was 21 weeks. Toxicity was generally tolerable; however, ototoxicity may be enhanced by this treatment. CDDP combined with cranial irradiation is tolerable and feasible, although close follow-up is recommended in case CDDP has to be temporarily interrupted.

Original languageEnglish (US)
Pages (from-to)109-113
Number of pages5
JournalJournal of neuro-oncology
Volume1
Issue number2
DOIs
StatePublished - Jun 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas'. Together they form a unique fingerprint.

  • Cite this